ADMA
$16.15
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Recent News
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
A Look At ADMA Biologics (ADMA) Valuation After Recent Share Price Swings
Recent performance snapshot and context ADMA Biologics (ADMA) has attracted fresh attention after a mixed stretch in the share price, with gains of about 1% over the past day contrasting with weaker moves over the past month and past 3 months. For investors, that split in recent returns often raises a practical question: whether the current price is starting to reflect company fundamentals like revenue, profitability and overall business momentum, or if sentiment is still the main driver...
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
Adma Biologics (ADMA) concluded the recent trading session at $15.15, signifying a +1.03% move from its prior day's close.
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA) reached $14.99 at the closing of the latest trading day, reflecting a -4.34% change compared to its last close.